C.

Access DB# 134470

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: C. Delacroix-M Examiner #: 71100 Date: 10-5-04

Art Unit: 1614 Phone Number 571-272-0572 Serial Number: 09/634,369

Mail Box and Bldg/Room Location. Results Format Preferred (circle): PAPER DISK E-MAIL

4 3C70 4 3A78

If more than one search is submitted, please prioritize searches in order of need. MEY

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention:

Inventors (please provide full names): Please see attached

Earliest Priority Filing Date:

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the method of claim 28. Claims are attached with key terms highlighted.

RECEIVED
OCT -5 2004
(STIC)

Please rush!

Thanks

C. Chan

Rush

RNOLD

****

STAFF USE ONLY

Searcher: Arnold

Searcher Phone #: 2-2532

Searcher Location:

Date Searcher Picked Up: 10/6/04

Date Completed: 10/6/04

Searcher Prep & Review Time:

Clerical Prep Time:

Online Time:

Type of Search

NA Sequence (#)

AA Sequence (#)

Structure (#)

Bibliographic

Litigation

Fulltext

Patent Family

Other

Vendors and cost where applicable

STN

Dialog

Questel/Orbit

Dr.Link

Lexis/Nexis

Sequence Systems

WWW/Internet

Other (specify)

PTO-1590 (8-01)

Printed 10/18/2001

APPLICATION NUMBER	FILING DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO
09/634,369	08/09/2000	514	1632	18989-004 (B

APPLICANT
JAMES K LIAO, WESTON, MASSACHUSETTS; DARRYL ZELDIN M.D, CHAPEL HILL, NORTH CAROLINA.

CONTINUING DOMESTIC DATA********
VERIFIED PROVISIONAL APPLICATION 60/148,434 08/11/1999

371 (NAT'L STAGE) DATA********
VERIFIED

FOREIGN APPLICATIONS********
VERIFIED

FOREIGN FILING LICENSE GRANTED 09/28/2000

Foreign priority claimed / 35 USC 119 (a-d) conditions met / Allowance / Verified and acknowledged	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
O yes O no / O yes O no O Met after / Examiner's Name Initials	NC	15	32	8

ADDRESS
MINTZ LEVIN COHN FERRIS GLOVSKY AND POPE
ONE FINANCIAL CENTER
BOSTON , MA 02111

TITLE
ANTI-INFLAMMATORY ACTIONS OF CYTOCHROME P450 EPOXYGENASE-DERIVED EICOSANOIDS

FILING FEE RECEIVED	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT NO. _____ for the following:	O All Fees O 1.16 Fees (Filing) O 1.17 Fees (Processing Ext. of Time) O 1.18 Fees (Issue) O Other _____ O Credit
$****0		

Amendments to the Claims

1.-27. (Canceled)

28. (currently amended) A method for ~~preventing~~ reducing cell death from hypoxia-reoxygenation, comprising:

contacting a cell undergoing hypoxia reoxygenation with an effective amount of a composition of matter selected from the group consisting of epoxyeicosatrienoic acids (EETs), epoxyeicosatrienoic acid metabolic products, epoxyeicosatrienoic acid analogs, ~~and~~ dihydroxyeicosatrienoic acid analogs, and combinations thereof, wherein the epoxyeicosatrienoic acid analogs and dihydroxyeicosatrienoic acid analogs comprise an episulfide derivative; a sulfonamide derivative; an analog in which one or more EET olefins are removed; an analog in which an EET olefin is replaced with an acetylene group or a cyclopropane group; an analog in which an epoxide moiety is replaced with an oxitane or furan ring; or a heteroatom analog,

wherein the composition ~~prevents~~ reduces cell death in the cell undergoing hypoxia-reoxygenation.

29.-32. (Canceled)

33. (Currently Amended) The method of claim 28, wherein contacting a cell comprises administration of EETs, epoxyeicosatrienoic acid metabolic products, epoxyeicosatrienoic acid analogs, ~~and~~ dihydroxyeicosatrienoic acid analogs, or combinations thereof to a subject, wherein the epoxyeicosatrienoic acid and dihydroxyeicosatrienoic acid analogs comprise an episulfide derivative; a sulfonamide derivative; an analog in which one or more EET olefins are removed; an analog in which an EET olefin is replaced with an acetylene group or a cyclopropane group; an analog in which an epoxide moiety is replaced with an oxitane or furan ring; or a heteroatom analog.

34. (Previously presented) The method of claim 33, wherein the administration comprises producing EETs from a cytochrome P450 epoxygenase.

35. (Previously presented) The method of claim 34, wherein the EET is [11,12]-EET, [14,15]-EET, or combinations thereof, and wherein the epoxyeicosatrienoic acid metabolic product is [11,12]-DHET.

36. (Previously presented) The method of claim 34, wherein the cytochrome P450 epoxygenase is selected from the group consisting of CYP1A, CYP2B, CYP2C, CYP2E, and CYP2J enzymes.

37. (Previously presented) The method of claim 36, wherein the CYP2J enzyme is a mammalian homologue of CYP2J2.

38. (Previously presented) The method of claim 37, wherein the mammalian homologue is human CYP2J2.

39. (Previously presented) The method of claim 37, wherein the mammalian homologue is rat CYP2J3 or mouse CYP2J5.

40. (Previously presented) The method of claim 28 wherein the EET is [11,12]-EET or [14,15]-EET, and wherein the epoxyeicosatrienoic acid metabolic product is [11,12]-DHET.

41. (new) The method of claim 28, wherein the cell is contacted with an effective amount of a composition of matter comprising epoxyeicosatrienoic acids (EETs).

42. (new) The method of claim 28, wherein the cell is contacted with an effective amount of a composition of matter comprising epoxyeicosatrienoic acid metabolic products.

43. (new) The method of claim 28, wherein the cell is contacted with an effective amount of a composition of matter comprising an episulfide derivative.

44. (new) The method of claim 28, wherein the cell is contacted with an effective amount of a composition of matter comprising a sulfonamide derivative.

45. (new) The method of claim 28, wherein the cell is contacted with an effective amount of a composition of matter comprising an analog in which one or more EET olefins are removed.

46. (new) The method of claim 28, wherein the cell is contacted with an effective amount of a composition of matter comprising analogs in which the EET olefins are replaced with an acetylene group or a cyclopropane group.

47. (new) The method of claim 28, wherein the cell is contacted with an effective amount of a composition of matter comprising an analog in which an epoxide moiety is replaced with an oxitane or furan ring.

48. (new) The method of claim 28, wherein the cell is contacted with an effective amount of a composition of matter comprising a heteroatom analog.

49. (new) The method of claim 45, wherein the analog in which one or more EET olefins are removed comprises an epoxyeicosadienoic acid, an epoxyeicosamonoenoic acid, or an epoxyeicosanoic acid.

50. (new) The method of claim 33, wherein contacting a cell comprises administration of an effective amount of a composition of matter comprising epoxyeicosatrienoic acids (EETs) to the subject.

51. (new) The method of claim 33, wherein contacting a cell comprises administration of an effective amount of a composition of matter comprising epoxyeicosatrienoic acid metabolic products to the subject.

52. (new) The method of claim 33, wherein contacting a cell comprises administration of an effective amount of a composition of matter comprising an episulfide derivative to the subject.

53. (new) The method of claim 33, wherein contacting a cell comprises administration of an effective amount of a composition of matter comprising a sulfonamide derivative to the subject.

54. (new) The method of claim 33, wherein contacting a cell comprises administration of an effective amount of a composition of matter comprising an analog in which one or more EET olefins are removed to the subject.

55. (new) The method of claim 33, wherein contacting a cell comprises administration of an effective amount of a composition of matter comprising an analog in which the EET olefins are replaced with an acetylene group or a cyclopropane group to the subject.

56. (new) The method of claim 33, wherein contacting a cell comprises administration of an effective amount of a composition of matter comprising an analog in which an epoxide moiety is replaced with an oxitane or furan ring to the subject.

57. (new) The method of claim 33, wherein contacting a cell comprises administration of with an effective amount of a composition of matter comprising a heteroatom analog to the subject.

58. (new) The method of claim 54, wherein the analogs in which one or more EET olefins are removed comprise an epoxyeicosadienoic acid, an epoxyeicosamonoenoic acid, or an epoxyeicosanoic acid.